Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized and priced approximately $5,000,000,000 (equivalent) of its debut sustainability-linked senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $4,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings to (i) fund the announced tender offer to purchase, f

Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes

A recent tentative ruling in the California opioid trial in favor of the pharmaceutical manufacturers should catalyze a nationwide settlement.

TEVA Stock: California Ruling De-Risks Story; Upside To $25

AbbVie

Endo International

Johnson & Johnson

A California judge cleared four drugmakers of liability after a monthslong trial accusing the companies, including Johnson & Johnson JNJ, +0.09% and Endo International PLC ENDP, +8.94% , of causing widespread opioid addiction in the state.

The Wall Street Journal: Opioid makers cleared of liability in California lawsuit

PARSIPPANY, N.J.--(BUSINESS WIRE)--Today, Orange County, California, Superior Court Judge Peter Wilson issued a decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland and that Teva did not make any false or misleading statements in connection with marketing prescription opioids in California. While we are pleased that the Court in California made this determination, a clear win for the many patients in the US w

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids

A California judge on Monday said he would rule against several large counties who accused four drugmakers of fueling an opioid epidemic, saying they had failed at trial to prove their $50 billion case.

California judge rules for drugmakers in major opioid lawsuit

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo for schizophrenia patients who underwent stabilization on oral risperidone.  Results showed treatment with TV-46000 (overall, q1m or q2m) significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24, and demonstrated a significant increase in proportions maintaining stability.

Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial

TEVA stock is down irrationally after its quarterly earnings report. Shares traded at a 2021 forward P/E in the 3 times range.

Five Considerations After Teva Pharmaceuticals' Q3 Report

Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.

Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down

The pharmaceutical giant whiffs on both the top and bottom lines in its Q3.

Why Teva Pharmaceutical Industries Fell Today

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2021 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q3 sales reached $3.89 billion, shrinking 2% Y/Y or 3% in local currency terms, missing the consensus of $4.03 billion. The decrease was mainly due to lower revenues in the North America segment, related primarily to Copaxone and generic products.

Teva Q3 Earnings Fall Short Of Expectations; Reaffirms FY21 Guidance

Teva Pharmaceuticals Inc. TEVA, -4.79% swung to a profit in the third quarter, although profit and revenue fell below Wall Street estimates.

Teva shares slump premarket after earnings fall short of estimates

Israel-based Teva Pharmaceutical Industries reported third-quarter profit that missed estimates, citing lower North American sales while Huntington's disease treatment Austedo and migraine product Ajovy continue to show revenue gains.

Teva Pharm Q3 profit misses estimates on lower North American sales

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $3,500,000,000 (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.250% Senior Notes due 2023, ISIN XS1211040917, issued by Teva Pharmaceutica

Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes. The notes offering reflects Teva's strong environmental, social and governance (ESG) commitment to some of the greatest challenges of our time by setting novel ambitious targets to increase access to medicines in low and middle-income countries by 150%, and new ambitious climate action targets, includin

Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021. Mr. Kåre Schultz, Teva's President and CEO, said, "I am very happy with our solid performance in the third quarter of 2021, especially our strong cash flow and continued momentum with key brands. Our results were driven by robust performance of AJOVY® in the U.S., Europe and Japan as well as U.S. sales of AUSTEDO®, our novel therapy for th

Teva Reports Third Quarter 2021 Financial Results

TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. Under the terms of the agreement and pending regulatory

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Shareholders of Teva Pharmaceutical Industries ( TEVA , Financial) thave now taken a multi-year beating. Since the company hit an all-time high in 2015 and bit off more than it can chew, over-paying for the Actavis acquisition, the company has gone from bad to worse.

Teva Has Turned the Corner

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

Biogen

On Monday, Biogen Inc. (NASDAQ:BIIB) shares edged higher 1% after Teva Pharmaceutical Industries Ltd (TLV:TEVA) settled the Vumerity lawsuit. The lawsuit claimed that Teva's proposed generic version of Vumerity would violate three Alkermes Plc (NASDAQ:ALKS) patents for the multiple sclerosis drug.

Is Biogen stock a buy after Teva settled the Vumerity patent lawsuit?

Bristol-Myers

General Motors

Mastercard

Visa

Riding the Oracle of Omaha's coattails has long been a moneymaking strategy.

5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has temporarily stopped drug production at its Irvine plant in California to address issues raised by the FDA after a recent inspection. The Company did not specify the issues raised by the agency.

Teva Stops Production At U.S. Plant After FDA Concerns: Reports

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2021 on Wednesday, October 27, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 9

Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021

The price of Teva Pharmaceutical stock has seen a rise of 14% in the last five trading days, while it is up 6% over the last month (twenty-one trading days). The recent rise came after the company announced a settlement with the state of Louisiana for opioid-related claims.

Is A Fall Imminent For Teva Stock After Its Recent Rally?

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 8 presentations examining Phase 2b/3 data, pooled analyses and open-label extension (OLE) study data for AJOVY (fremanezumab-vfrm) injection will be presented at the 25th World Congress of Neurology (WCN), taking place virtually on Oct. 3-7, 2021. “The data being presented at this year's WCN meeting aid in expanding our knowledge of migraine so we can continue to

News for Teva Pharmaceutical Stock (TEVA)